PLoS ONE (Jan 2021)

Deletion of arginase 2 attenuates neuroinflammation in an experimental model of optic neuritis.

  • Amritha A Candadai,
  • Fang Liu,
  • Abdelrahman Y Fouda,
  • Moaddey Alfarhan,
  • Chithra D Palani,
  • Zhimin Xu,
  • Ruth B Caldwell,
  • S Priya Narayanan

DOI
https://doi.org/10.1371/journal.pone.0247901
Journal volume & issue
Vol. 16, no. 3
p. e0247901

Abstract

Read online

Vision impairment due to optic neuritis (ON) is one of the major clinical presentations in Multiple Sclerosis (MS) and is characterized by inflammation and degeneration of the optic nerve and retina. Currently available treatments are only partially effective and have a limited impact on the neuroinflammatory pathology of the disease. A recent study from our laboratory highlighted the beneficial effect of arginase 2 (A2) deletion in suppressing retinal neurodegeneration and inflammation in an experimental model of MS. Utilizing the same model, the present study investigated the impact of A2 deficiency on MS-induced optic neuritis. Experimental autoimmune encephalomyelitis (EAE) was induced in wild-type (WT) and A2 knockout (A2-/-) mice. EAE-induced cellular infiltration, as well as activation of microglia and macrophages, were reduced in A2-/- optic nerves. Axonal degeneration and demyelination seen in EAE optic nerves were observed to be reduced with A2 deletion. Further, the lack of A2 significantly ameliorated astrogliosis induced by EAE. In conclusion, our findings demonstrate a critical involvement of arginase 2 in mediating neuroinflammation in optic neuritis and suggest the potential of A2 blockade as a targeted therapy for MS-induced optic neuritis.